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Available online xxxxBackground: In search of novel biomarkers of response to bevacizumab in metastatic colorectal cancer (mCRC), we
analyzed the expression and prognostic role of several proteins related to angiogenesis.Methods:A retrospective,mul-
ticenter study on 80 surgical samples from mCRC patients treated in first line with bevacizumab plus chemotherapy
was accomplished. The following proteins were analyzed by immunohistochemistry: hERG1 potassium channel, β1-
integrin, pAKT, NFkB, HIF-1α, HIF-2α, p53, VEGF-A, GLUT-1, and CA-IX. Data were analyzed in conjunction with
the clinicopathological characteristics of the patients, KRAS status, response to bevacizumab, and follow-up. Results:
(1) All the proteins were expressed in the samples, with statistically significant associations between HIF-1α and gen-
der, HIF-2α and left colon, hERG1 andVEGF-A, β1-integrin andHIF-2α, GLUT-1 and bothHIF-1α andHIF-2α, and CA-
IX and VEGF-A. (2) At the univariate analysis, positivity for hERG1, VEGF-A, and the active form of HIF-2α (aHIF-2α),
and the G3 histological grade showed a positive impact on progression-free survival (PFS). (3) hERG1 and aHIF-2α
maintained their positive impact on PFS at the multivariate analysis. (4) hERG1 behaved as a protective factor for
PFS independently on KRAS status. Conclusions: hERG1 and aHIF-2αmight help to identify patients who would ben-
efit from bevacizumab treatment.Introduction
The management of metastatic colorectal cancer (mCRC) has deeply
changed in the last 20 years thanks to the use of either anti-EGFR antibodies
or antiangiogenic therapies, mainly anti–VEGF-A antibodies. According to
NCCN guidelines (Version 2.2017), the main determinants for the thera-
peutic choices are the localization of the tumor (right colon, left colon, or
rectum), in addition to its molecular features (MSI, CIMP, BRAFmutations,
RASmutational status, SCNA expression) [1]. For example, RAS wild-typeD., Ph.D. Department of Clinical
Viale GB Morgagni, 50, 50134
li).left-sided tumors can be treated with anti-EGFR antibodies plus chemother-
apy, whereas right-sided tumors, either RASwild type or mutated, are pref-
erentially treated with chemotherapy, with the eventual addition of anti–
VEGF-A antibodies, similarly to all the RASmutated tumors [1]. To accom-
plish proper antiangiogenic therapies, different agents with peculiar mech-
anisms of action have been developed in the last years and tested in several
clinical trials [2,3].
The first antiangiogenic factor to be developed was a humanized anti–
vascular endothelial growth factor (VEGF)-A monoclonal antibody,
bevacizumab (BV) [4,5]. Thanks to numerous clinical trials, the combina-
tion of BV with a fluoropyrimidine-based chemotherapy emerged to be an
efficient option in bothfirst and second lines [6–12].Moreover, several ran-
domized studies showed that a prolonged inhibition of angiogenesis be-
yond the clinical evidence of disease progression could improve mCRC
patients' survival. Hence, it is becoming mandatory to identify appropriate
biomarkers associated with a positive response to BV, to orientate
J. Iorio et al. Translational Oncology 13 (2020) 100740treatment choice also beyond first line, with the aim to optimize the cost/
benefit ratio of antiangiogenic strategies for eachmCRC patient [13]. How-
ever, in spite of several attempts, no clinically validated appropriate bio-
markers were found, and the choice of the second-line treatment is
mainly based on physicians' preferences. In fact, although the plasma levels
of VEGF-A were first addressed as a putative indicator of response to BV in
mCRC, several retrospective analyses failed to confirm these findings [14].
Two single-nucleotide polymorphisms of the VEGF-A gene [1154G.A
(rs1570360) and 1405C.G (rs2010963)] were found to be associated with
an increase of both overall (OS) and progression-free (PFS) survival [15].
However, their effectiveness to identify patients more suitable to respond
to anti–VEGF-A agents still needs to be confirmed in larger trials. The
same lack of confirmation in larger clinical settings also occurred for the ex-
pression of VEGF-A unrelated biomarkers which were found to be associ-
ated with survival outcomes: apolipoprotein E, vitamin D-binding protein,
and angiotensinogen [16]. Finally, two different studies indicated that a
high serum lactic dehydrogenase pretreatment level behaves as a predictor
of efficacy of first-line BV-based therapy [17,18]. However, an Italian
Group for the Study of Digestive Tract Cancers (GISCAD) phase II prospec-
tive trial failed to confirm the predictive values of pretreatment serum lactic
dehydrogenase [19]. Overall, clinically validated biomarkers capable to se-
lect patients that would likely respond to BV plus chemotherapy, and could
be also suitable to continue BV-based therapies, are still needed [20].
Among the various angiogenesis-related cancer biomarkers, we studied
the potassium channel encoded by the human ether-a-go-go-related gene 1
(KCNH2 or hERG1), a protein widely expressed in several types of human
cancers, including CRC [21–23]. In particular, hERG1 is the starting hub
of a proangiogenic signaling pathway activated by cell adhesion to the ex-
tracellular matrix that regulates the expression of both HIF-1α and Hif-2α
through the phosphorylation of Akt and the ensuing activation of NFkB
[24]. Such pathway leads to VEGF-A secretion and hence sustains angio-
genesis and metastatic spread in CRC preclinical models [24]. The rele-
vance of this pathway also emerged by the finding that the combined
treatment with hERG1 blockers and BV inhibits both local tumor growth
and metastatic spread in preclinical models of CRC [24,25]. Furthermore,
hERG1 expression associates with that of the glucose transporter GLUT-1
and the membrane carbonic anhydrase IX (CA-IX) in primary samples
from TNM stages I-III CRC patients and can predict disease relapse [26,27].
Based on the above preclinical data, we analyzed the expression of sev-
eral proangiogenic proteins, directly or indirectly linked to hERG1 channels
and their downstream signaling pathway, in surgical samples from mCRC
patients and tested their prognostic impact for response to BV-based
therapies.
Materials and Methods
Patients
A multicenter retrospective study was conducted on 80 mCRC patients
treated in first line with BV plus chemotherapy between June 2010 and
June 2017 in three Italian institutions. The selection of patients was per-
formed by medical oncologists of the hospitals involved in the study
(Azienda Ospedaliero-Universitaria Careggi, Florence; Campus Bio-
Medico University, Rome; Spedali Civili Hospital, Brescia). Afterwards,
paraffin-embedded samples were retrieved from the Pathological Anatomy
Sections of the above-mentioned institutions: i) 35 samples were collected
from archives of the Section of Pathological Anatomy, Department of Ex-
perimental and Clinical Medicine, University of Florence, Florence; ii) 36
samples from the Section of Pathological Anatomy, Department of Pathol-
ogy, Campus Bio-Medico University of Rome; and iii) 9 samples from the
Pathology Section of the Spedali Civili Hospital, Brescia. All the patients en-
rolled in the study were classified as cTNM stage IV; paraffin-embedded
samples were classified as pTNM stage IV (i.e., with synchronous metasta-
ses defined as developed within 3-12 months from surgery) in 76 samples,
while 4 patients were operated for a TNM stage III disease (and therefore
developed metachronous metastases after 12 months).2Best response and progression were defined according to RECIST
criteria. KRAS mutation analysis was performed by either MALDI-TOF
(Sequenom) or pyrosequencing.
The demographic and clinicopathological characteristics and survival as
well as KRASmolecular status of the patients enrolled in the study are re-
ported in Supplementary Table S1.
Immunohistochemistry (IHC)
Eighty formalin-fixed, paraffin-embedded mCRC samples belonging to
TNM stage IV (76 samples) and III (4 samples) that further progressed to
TNM stage IV were analyzed for the expression of the following proteins:
hERG1, β1-integrin, pAKT, NFkB, HIF-1α, HIF-2α, p53, VEGF-A, GLUT-1,
and CA-IX. IHC was carried out on 7-μm sections on positively charged
slides. After dewaxing and rehydrating the sections, endogenous peroxi-
dases were blocked with a 1% H2O2 solution in phosphate-buffered saline
(PBS). Subsequently, antigen retrieval was performed with different proce-
dures, depending on the antibody used: 1) by treatment with proteinase K
(5 μg/ml) in PBS at 37°C for 5 minutes (for hERG1, VEGF-A, GLUT-1, and
CA-IX staining) or 2) by heating the samples in a microwave oven at 600
W in citrate buffer pH 6.0 for 15 (for pAKT, NFkB, HIF-1α, HIF-2α, and
p53 staining) or 20 minutes (for β1-integrin staining). The following anti-
bodies were used: anti-hERG1 monoclonal antibody (MCK Therapeutics;
0,005 μg/μl), anti-BETA1 integrin [monoclonal antibody (4B7R) to Integrin
beta 1, Abcam, 1:35], anti-pAKT [monoclonal antibody p-Akt1/2/3 (B-5),
Santa Cruz Biotechnology, 1:100], anti-NFkB [polyclonal antibody anti-
NFkB p65 (A): SC-109, Santa Cruz Biotechnology, 1:100], anti-VEGF-A
[polyclonal antibody anti-VEGF-A (A-20), Santa Cruz Biotechnology,
1:100], anti-Glut-1 (polyclonal rabbit anti-human GLUT1 H-43, Santa
Cruz Biotechnology, 1:100), anti-HIF-1α [monoclonal antibody HIF-1
alpha Antibody (HA111), Novus Biologicals, 1:100], anti-HIF-2 alpha
(polyclonal antibody HIF-2 ALPHA/EPAS; Novus Biologicals, 1:100),
anti–CA-IX monoclonal antibody (monoclonal murine antibody M75, de-
scribed in [28]), and anti-p53 monoclonal antibody (Dako Cytomation,
1:50). Incubation with the primary antibodies was carried out overnight
at 4°C, except for the anti-p53 antibody, which was incubated for
30 minutes at room temperature, and for anti–β1-integrin antibody,
which was incubated for 2 hours at room temperature. Immunostaining
was performed with a commercially available kit (PicTure max kit;
Invitrogen) according to the manufacturer's instructions.
Scoring System Assessment
Immunohistochemistry slides were scored by two independent opera-
tors (J.I. and E.L.). A specific scoring system was applied for each protein.
Previously published scoring systems [26] were applied to hERG1, p53,
VEGF-A, GLUT-1, and CA-IX. Samples were considered positive when the
percentage of stained cells was higher than the assigned threshold: for
hERG1 and β1-integrin, a cutoff of 50% was applied; for p53, VEGF-A,
CA-IX, and pAKT, a cutoff of 10% was used; and for GLUT-1, a cutoff of
1% was set. The localization of staining was evaluated for NFkB, HIF-1α,
and HIF-2α, and only samples where at least 1% of tumor nuclei was la-
beled were considered positive. Normal epithelium, stroma, and areas of
necrosis were not estimated. The applied scoring system is shown in Sup-
plementary Table S2.
Statistical Analysis
Throughout the manuscript, continuous variables were expressed as
mean ± SD, and categorical ones were expressed as absolute and relative
frequencies. The correlations between continuous and categorical variables
were analyzed with Pearson's correlation coefficient, while for categorical
variables, the Pearsonχ2 test or the Fisher's exact testwas usedwhen appro-
priate. P value of χ2 test was applied when all frequencies were >5; P value
of Fisher's exact test was usedwhen at least one frequencywas≤5. In order
to define the differences in either progression of disease rate or survival rate
Figure 1. Representative images of samples expressing the markers of interest. IHC experiments and scoring assessment were performed as described in Materials and
Methods and Supplementary Table S2. Bar: 100 μm. The marker under investigation, percentages, and absolute values of samples with a positive expression or with
expression of the active form of the marker are reported on the top of each images.
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Cox's model was adopted, including log-rank test and Kaplan-Meier (KM)
curves. Hazard ratios and 95%Wald's confidence intervals were computed.
A multivariate Cox's model (backward selection; covariates were retained
in the model if the P value was< .05) was computed to define the possible
markers, or combination of markers, associated with either the progression
of the disease or the death of the patient. A two-sided P value < .05 was
considered to be statistically significant.
Results
Clinical Characteristics
The mean age of the patients was 65.8± 1.2 years (range 34-79), with
the majority of patients belonging to the age group≥65.8, in agreement
with the characteristics of the disease [29]. Of the 80 patients, 30
(37.5%) were females and 50 (62.5%) were males. Thirty-four tumors
(43%) were located in the right colon (right colon + transverse), 29
(36%) in the left colon (left colon + sigmoid colon), and 13 (16%) in the
rectum. Sixty tumors (75%) were classified as G2, 4 (5%) as G1, and 9
(11%) as G3. Twenty-six (33%) had wild-type KRAS, and 47 (59%) had
KRAS mutations. Forty-five out of 80 (56%) patients had disease progres-
sion, and 50/80 (62%) died during the time of follow-up. In accordance
to RECIST criteria, 9 (11%) patients had a complete response, 18 (23%)
presented a partial response, 31 (39%) had stable disease, and 16 (20%)
underwent progression. The distribution of the demographic and clinico-
pathological characteristics and survival of the cohort are shown in Supple-
mentary Table S1.
Immunohistological Findings
The expression of the following proteins was determined by IHC on
paraffin-embedded samples: hERG1, β1-Integrin, pAKT, NFkB, HIF-1α,
HIF-2α, p53, VEGF-A, GLUT-1, and CA-IX. Representative pictures of
each protein, along with the percentage of patients positive to the bio-
marker (according to the scoring system described in Materials and
Methods and summarized in Supplementary Table S2), are shown in
Figure 1. hERG1 staining was detected mainly on the plasma membrane,
with a weak staining also at the cytoplasmic level, due to the presence of
immature forms of hERG1 in the cytoplasm as previously described [30].
β1-Integrin was detected in the cytoplasm of tumor cells because the anti-
body recognizes a β1-integrin specific intracellular epitope, although the3main localization of the protein is on the plasma membrane. pAKT and
VEGF-A were expressed in the cytoplasm of neoplastic cells, as expected.
NFkB, HIF-1α, and HIF-2α staining could be detected either in the cyto-
plasm or in the nuclei of tumor cells, but only samples displaying a nuclear
staining were considered positive since the nuclear localization mirrors an
“active” protein (aHIF-1α and aHIF-2α, respectively). p53 labeled tumor
nuclei. GLUT-1 stained plasma membrane and cytoplasm and CA-IX were
expressed only on the plasmamembrane of neoplastic cells. All the samples
were scored as described inMaterials andMethods and summarized in Sup-
plementary Table S2.
Relationships Between Biological Markers and Clinical Characteristics
A hERG1 positive signal was observed in 86.3% (69/80) of patients. β1-
Integrin was detected in 55% (44/80) of samples, pAKT in 69% (55/80),
NFkB in 48% (38/80), aHIF-1α in 56.6% (43/76), aHIF-2α in 42% (34/
80), p53 in 49% (39/80), VEGF-A in 78% (62/80), GLUT-1 in 78% (62/
80), and CA-IX in 51% (41/80) (Figure 1). Patients expressing hERG1,
β1-integrin, and VEGF-A were 77% (34/80) also positive for either aHIF-
1α or aHIF-2α, or both. Thirty of 80 samples were positive for hERG1 al-
though negative for β1-integrin, and 73% of them were positive for
VEGF-A. Overall, the pathway linking hERG1 toVEGF-A is apparently oper-
ative in mCRC primary samples (Supplementary Figure S1). Indeed, only
four patients were negative for both hERG1 and VEGF-A.
Statistically significant associations emerged between aHIF-1α and gen-
der (P= .020; aHIF-1α andmale gender) and between aHIF-2α and tumor
localization (P= .004; HIF-2α active form and left colon) (Table 1).
The following statistically significant associations between molecular
markers emerged: hERG1 and VEGF-A (P= .049; positive hERG1 and pos-
itive VEGF-A), β1-integrin and HIF-2α (P= .016; positive β1-integrin and
aHIF-2α), GLUT-1 and HIF-1α (P = .045; positive GLUT-1 and aHIF-1α),
GLUT-1 and HIF-2α (P= .003; positive GLUT-1 and aHIF-2α), and CA IX
and VEGF-A (P= .024, positive CA-IX and positive VEGF-A) (Table 1).
Impact on Survival
The cohort under study had a median PFS of 336 ± 43 days and a me-
dian OS of 804 ± 39 days. The univariate analysis showed that hERG1,
aHIF-2α, and VEGF-A had a significant impact on PFS, with hazard ratio
(HR) values <1, indicating their role as protective factors (Table 2). The
KM curves relative to the three biomarkers (Figure 2) clearly show that
Table 1
Statistically Significant Associations Between Biological Markers and Clinical
Characteristics
Parameter/Marker Marker P Value
Gender iHIF-1α aHIF-1α
.020*Female 17 (22%) 11 (15%)
Male 16 (21%) 32 (42%)
Localization iHIF-2α aHIF-2α .004*
Right colon 25 (54%) 12 (36%)
Left colon 10 (22%) 19 (58%)
Rectum 11 (24%) 2 (6%)
VEGF-A hERG1− hERG1 +
.049^Negative 5 (6%) 13 (16%)
Positive 6 (8%) 56 (70%)
CA-IX− CA-IX +
.024^Negative 13 (16%) 5 (6%)
Positive 26 (32%) 36 (45%)
HIF-2α β1-integrin− β1-Integrin +
.016*Inactive 26 (33%) 20 (25%)
Active 10 (13%) 24 (30%)
GLUT-1 iHIF-1α aHIF-1α
.045*Negative 11 (15%) 6 (12%)
Positive 22 (25%) 37 (49%)
iHIF-2α aHIF-2α
.003^Negative 16 (20%) 2 (3%)
Positive 30 (38%) 32 (40%)
Absolute values and percentages (in parentheses) are indicated. P value of χ2 test
(indicated with *) is reported when all frequencies are >5; P value of Fisher's
exact test (indicatedwith ^) is reportedwhen at least one frequency is≤5. “a”: sam-
ples with active protein; “I”: samples with inactive protein.
Table 2
Univariate PFS Analysis
HR (95% CI) P (LR Test)
hERG1
Negative 1 (Ref) .015
Positive 0.41 (0.20-0.84)
HIF-2α
Inactive 1 (Ref) .027
Active 0.49 (0.26-0.92)
GLUT-1
Negative 1 (Ref) .402
Positive 0.75 (0.39-1.46)
KRAS status
Wild type 1 (Ref) .601
Mutated 0.84 (0.44-1.60)
NFkB
Inactive 1 (Ref) .168
Active 0.65 (0.35-1.20)
β1-Integrin
Negative 1 (Ref) .427
Positive 0.79 (0.43-1.42)
HIF-1α
Inactive 1 (Ref) .683
Active 0.88 (0.48-1.62)
pAKT
Negative 1 (Ref) .422
Positive 0.77 (0.41-1.45)
VEGF-A
Negative 1 (Ref) .008
Positive 0.42 (0.22-0.80)
p53
Negative 1 (Ref) .688
Positive 1.13 (0.62-2.04)
CA-IX
Negative 1 (Ref) .417
Positive 0.78 (0.43-1.42)
Gender
Female 1 (Ref) .322
Male 1.37 (0.73-2.56)
Grading
G3 1 (Ref) .013
G1 16.44 (1.81-149.10)
G2 7.65 (1.04-56.07)
Localization
Rectum 1 (Ref) 1.000
Right colon 0.78 (0.33-1.84)
Left colon 1.06 (0.32-3.54)
Univariate analysis was performed using Cox's model, including log-rank test and
KM curves. HRs and 95% Wald's confidence intervals were computed as described
in Materials and Methods section. P values of log-rank test, HRs, and 95% Wald's
confidence intervals are reported. Median PFS: 336± 43 days. Significant P values
are in bold and underlined.
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to negative patients.
Among the clinicopathological features (see Supplementary Table S1),
only the tumor grading had a significant impact on PFS, so that patients
with a less differentiated (G3) primary tumor had a better response to BV
(Table 2; see also the KM curve in Figure 2).
The multivariate analysis, using hERG1, aHIF-2α, VEGF-A ,and all the
clinicopathological features, showed that hERG1 positivity and the pres-
ence of an active form of HIF-2α significantly impacted on PFS. In particu-
lar, both hERG1 positivity (P = .012; HR: 0.362; 95% Wald confidence
limits: 0.163-0.803) and aHIF-2α (P= .027; HR: 0.400; 95% Wald confi-
dence limits: 0.178-0.902) correlated with a longer PFS, hence behaving
as biomarkers of a positive response to treatment with BV (Table S3). To
confirm the impact of the two biomarkers (hERG1 and aHIF-2α), we per-
formed another multivariate PFS analysis with all the proangiogenic
markers and the KRAS status. From this analysis, only hERG1 positivity
showed a statistically significant impact. Also, in this case, hERG1 behaved
as a protective factor for treatment with BV (P = .002; HR: 0.302; 95%
Wald confidence limits: 0.139-0.655) (Supplementary Table S4).
None of the tested markers and clinicopathological characteristics had
an impact on OS (median OS 804 ± 39 days), and no statistically signifi-
cant association was found between best response (defined according to
RECIST Criteria) and the expression of any of the proteins tested and clini-
copathological features.
Patients were hence stratified into four groups on the basis of the posi-
tivity or negativity for any biological marker including KRAS mutational
status, and a risk analysis was performed. Statistically significant differ-
ences in PFS emerged for the combinations hERG1-pAKT, hERG1-NFkB,
hERG1–aHIF-1α, hERG1–aHIF-2α, hERG1–VEGF-A, and hERG1-KRAS
(Supplementary Table S3). In particular, 1) in the combinations hERG1-
pAKT, hERG1-NFkB and hERG1–HIF-1α, patients expressing hERG1 had
a longer PFS than hERG1-negative subjects, regardless of the other marker
(Supplementary Figure 2S); 2) in the combinations hERG1–aHIF-2α and
hERG1–VEGF-A, patients positive for either biomarker(s) had a longer
PFS compared to patients negative for both proteins; 3) in the combination
KRAS-hERG1, patients positive for hERG1, either with a mutated or wild-
type KRAS, had a longer PFS compared to patients that do not express
hERG1 (Figure 3, A, B, and C).4Discussion
The identification of biomarkers correlated with a positive response
to BV plus chemotherapy in mCRC patients is still a big challenge. Ap-
propriate biomarker(s) would help to select those patients eligible for
BV treatment in first line and its prolongation in second line. We got
strong preclinical data showing the existence, in CRC cells, of a
proangiogenic signaling pathway centered on the expression and activ-
ity of hERG1 potassium channels [26]. Based on these data, we
performed a multicenter retrospective study in which several
angiogenesis-related proteins linked to such pathway were analyzed in
samples belonging to mCRC patients treated in first line with BV plus
chemotherapy. The main results of our study were as follows: 1) all
the members of the signaling pathway downstream to hERG1 channels
are expressed in CRC primary samples, showing different associations
among them; 2) both hERG1 and an active form of HIF-2α are prognos-
tic biomarkers of positive response to BV plus chemotherapy, as emerg-
ing from univariate and multivariate PFS analyses; and 3) the impact of
hERG1 on the positive response to BV plus chemotherapy occurs irre-
spective of the KRAS mutational status of the tumor sample.
Figure 2. KM curves of PFS. (A) hERG1 (negative: 10, positive: 35); (B) HIF-2α (inactive: 30, active: 15); (C) VEGF-A (negative: 15, positive: 30); (D) grading (G1: 4, G2: 34,
G3: 2). Only statistically significant curves are reported. “n”: negative samples; “p”: positive samples; “a”: samples with active protein; “I”: samples with inactive protein.
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identified to drive proangiogenic and prometastatic behaviors in CRC cell
lines turned out to be expressed with statistically significant associations
(Table 1 and Figure S1) in mCRC human primary samples. This finding in-
dicates that such pathway is operative also in vivo. Some specific associa-
tions merit attention. For instance, the associations between VEGF-A and
both hERG1 and CA-IX not only confirm what was previously detected in
stage I-III CRC [24] but further stress the relevance of the functional net-
work between hERG1, angiogenesis, and pH-regulating mechanisms.
Such network is emerging to drive tumor malignancy in several cancer
types including CRC [24–27,31–32]. A strong correlation between β1-
integrin and HIF-2α and between GLUT-1 and both HIF-1α and HIF-2α
also emerged. The former association agrees with the finding that hypoxia
and HIF (s) induce β1-integrin expression and activation [33]. The associa-
tion between GLUT-1 and HIF-1α is expected since the transcription of the
GLUT-1 gene is known to be under the control of HIF-1α [34]. It is surpris-
ing that we did not find an association between GLUT-1 and hERG1 as pre-
viously found in TNM stage I-III CRC patients, where the two proteins are
inversely associated and a low GLUT-1 with high hERG1 expression iden-
tifies a patient subgroup with a worse prognosis [24]. We proposed a
model in which GLUT-1 expression is high until hypoxia is present within
the tumor mass, to decline after reestablishment of normoxia, thanks to
hERG1 overexpression and the ensuing hERG1-triggered angiogenesis
[24]. On the contrary, in the cohort analyzed in the present paper
(i.e., only TNM stage IV, metastatic samples, treated in first line with BV),
GLUT-1 expression is higher than in TNM stage I-III patients (77.5% vs.
34.8%), as expected [35]. Furthermore, the association between hERG1
and GLUT-1 is lost, suggesting that metastatic lesions gather an indepen-
dent angiogenic state, in which the balance and interplay of the two
markers are no longer present, and both reach high expression levels.
aHIF-2α association with tumor localization (much HIF-2α active forms
in left-sided tumors) is conceivably related to the different biomolecular
features of right- and left-sided lesions [36]. For example, HIF-2α is5known to regulate the expression of the EGFR gene, which shows higher
levels in the tumors of the left colon [37]. Furthermore, our data showing
the relevance of HIF-2α give further support to the notion that, in colorectal
carcinomas, HIF-2α plays a key role in the angiogenesis, greater than HIF-
1α [37–39].Overall, the expression and correlation data we obtained sup-
port, in the human clinical setting, the conclusion we derived from model
cells in vitro, i.e., the relevance of hERG1 in driving angiogenesis and the
metastatic process in CRC, and its potential therapeutic translatability.
Furthermore, such data give a mechanistic explanation to the main re-
sults of the present paper, i.e., the positive impact on response to BV of
some components of the above signaling pathway, in particular hERG1
and the active form of HIF-2α. The impact of the different proangiogenic
biomarkers on patients' outcome was analyzed evaluating different clinical
parameters of response (PFS, OS, and best response), but a statistically rel-
evant association emerged only when evaluating the PFS. This is not a sur-
prise since several studies reported PFS as an appropriate surrogate of OS
and thus a good indicator for response to therapy [40].
At the univariate analysis, three proteins, hERG1, HIF-2α, and VEGF-A,
showed a significant impact, with patients positive for any of the three
markers having a longer PFS. Other biomarkers, such as CA-IX or GLUT-
1, shown to have a negative or positive impact, respectively, on OS in
TNM stages I-III cases [24] lose their relevance on the response to
antiangiogenesis treatment. Also, tumor localization had no impact on
PFS besides its correlation with aHIF-2α and its relevance in therapeutic
choice. While VEGF-A had no impact in TNM stages I-III, its expression pos-
itively impacted on PFS of stage IV patients treated with BV. This fact dis-
agrees with what was reported by Hedge et al. [14], who showed that
baseline levels of VEGF-A have a negative impact (HR >1) on survival of
mCRC patients treated with BV. Such discrepancy may suggest different
roles of the intracellular and extracellular (serum)VEGF-A in driving the re-
sponse to BV treatment.
Different from VEGF-A, both hERG1 and aHIF-2αmaintained their sig-
nificant, positive impact on PFS at the multivariate analysis, hence
Figure 3. KM curves of PFS obtained from the risk analysis. (A) Combination of
hERG1 and HIF-2α. Combinations are defined as follows: 00: hERG1 negative–
HIF-2α inactive; 01: hERG1 negative–HIF-2α active; 10: hERG1 positive–HIF-2α
inactive; 11: both hERG1 and HIF-2α active. hERG1 and HIF-2α (00: 7, 11: 30).
(B) Combination of hERG1–VEGF-A. 00: hERG1 negative–VEGF-A negative; 01:
hERG1 negative–VEGF-A positive; 10: hERG1 positive–VEGFA negative; 11: both
hERG1 and VEGF-A positive. hERG1 and VEGF-A (00: 5, 11: 56). (C)
Combination of hERG1 and KRAS status. For KRAS status, 01 indicates wild-type
KRAS and hERG1 positivity; 10 identifies mutated KRAS samples negative for
hERG1 expression; samples harboring KRAS mutations and positive for hERG1
are indicated with 11. Number of patients: 00 (3), 01 (12), 10 (7), and 11 (19).
Only statistically significant curves are reported. “n”: negative samples; “p”:
positive samples; “a”: samples with active protein; “I”: samples with inactive
protein.
J. Iorio et al. Translational Oncology 13 (2020) 100740configuring as independent prognostic factors of positive response to BV.
The impact of hERG1 and aHIF-2α emerged also when analyzing the com-
bined expression of the different biomarkers. Notably, mCRC patients
whose lesions were positive for both HIF-2α and hERG1 had a lower risk
of progression during BV plus chemotherapy treatment. From these results,
it is tempting to speculate that hERG1 is upstream to HIF-2α and of the
whole proangiogenic signaling pathway, thus confirming what was6previously shown in CRC cells. In the latter model, in fact, hERG1 activity
positively regulates HIF-2α expression and in turn VEGF-A secretion [26].
This implies that hERG1-positive patients with more aHIF-2α and greater
VEGF-A secretion would benefit from the block of VEGF-A through treat-
ment with BV, as shown by the survival analysis reported.
The relevance of hERG1 and its downstream pathway also emerges
from the finding that hERG1-positive patients with KRAS mutations have
a longer PFS than patients harboring the same mutation but negative for
hERG1. This result might have a clinical relevance because the evaluation
of KRASmutational status is the only approved predictive biomarker to de-
fine the treatment options for mCRC patients [41].
Conclusions
Overall, the results provided in this paper suggest the use of hERG1 and
aHIF-2α immunoreactivity to select patients suitable to be treated with BV,
in addition to chemotherapy, both in first and second line, irrespective of
the KRAS status or localization of the tumor. In other words, the simulta-
neous presence of both proteins behaves as a prognostic biomarker and,
once validated in an appropriate prospective clinical study, could be pro-
posed as a predictive factor for response to therapy with antiangiogenic
agents such as BV.
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